Notice Number: NOT-DA-18-020

Key Dates
Release Date: July 31, 2018

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants of the change in the funds available and anticipated awards for RFA-DA-19-002, "Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)”.

This funding opportunity is being offered as part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative.

The following change has been made in RFA-DA-19-002:

Part 2. Full Text of Announcement
Section II. Funds Available and Anticipated Number of Awards

Currently reads
Funds available and anticipated Number of Awards
NIDA intends to commit $10M in each fiscal year to a sufficient number of meritorious applications. NIDA intends to commit $10M in each fiscal year and to fund 3 to 4 grants per fiscal year.

Modified to read
Funds available and anticipated Number of Awards
NIDA intends to commit $70M in each fiscal year and to fund 20 grants per fiscal year.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Ivan D. Montoya, M.D., M.P.H.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5936
Email: [email protected]